US Patent

US8105626 — Granules containing acid-unstable chemical in large amount

Formulation · Assigned to Takeda Pharmaceutical Co Ltd · Expires 2026-09-27 · 0y remaining

Vulnerability score 65/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a formulation of granules containing a high concentration of an acid-unstable medicament, specifically a benzimidazole compound.

USPTO Abstract

It is intended to provide preparations such as capsules containing an acid-unstable medicament (in particular, a benzimidazole compound having an antiulcer effect, etc.) at a high concentration which are prepared by using about 12% by weight or more (based on the total granules) of the acid-unstable chemical and blending a basic inorganic salt therewith to give granules of about 600 μm or more in the average particle size.

Drugs covered by this patent

Patent Metadata

Patent number
US8105626
Jurisdiction
US
Classification
Formulation
Expires
2026-09-27
Drug substance claim
No
Drug product claim
Yes
Assignee
Takeda Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.